[THE SERUM LEVEL OF TOTAL AND OLIGOMERIC FRACTIONS OF SOLUBLE MOLECULES CD38 UNDER MALIGNANT TUMORS OF CERVIX AND UTERINE BODY].

The immune-enzyme analysis was applied using anti-CD38 monoclonal antibodies to detect serum content of total (sCD38) and oligomeric fractions of soluble molecules CD38 (ol.sCD38) in patients with cervix cancer and malignant neoplasms of uterine body. The three- and four-fold increasing of serum level of sCD38 is demonstrated both under cervix cancer and malignant neoplasms of uterine body. The level of ol.sCD38 decreased in patients with cervix cancer and increased in case of patients with malignant neoplasms of uterine body. The serum content of ol.sCD38 was increased under adenocarcinoma of uterus and glandular epidermoid cancer. The content of sCD38 increased under adenocarcinoma of uterus but decreased under sarcoma of uterus. The highest level of soluble molecules of CD38 was established in patients with highly differentiated tumors and under invasion into endometrium but not into miometrium. On the whole, alterations in content of soluble molecules CD38 are associated with characteristics of tumor process that indicates at their monitoring significance under malignant neoplasms of uterus.

[Heterogeneous expression of CD38 gene in tumor tissue in patients with colorectal cancer].

The CD38 gene codes a membrane protein which takes part in cell adhesion and catalyzes the formation of cyclic ADP-ribose. Using RT-PCR method we tested the presence of full-size and alternative forms of mRNA CD38 in samples of tumor tissue of patients with colorectal cancer and in tumor cell lines. It was shown that there are the cells in the tumor tissue which expressed CD38 gene. In tumor tissue of patients the alternative form of mRNA CD38 was detected less frequently than full-size form. Cells of lines Colo-205, T-84, HCT15 and HCT116 contained mRNA CD38, in cells of lines Caco-2 and SW-620 mRNA CD38 was absent. In cells of tumor tissue on the first stage of colorectal cancer CD38 gene was expressed in 100% of cases. On the second, third and fourth stages of the disease gene expression was observed less often. The frequency of mRNA CD38 detection not depend on tumor localization, tumor grade and presence of metastases. Using method of restriction analysis CpG methylation was detected in binding sites of transcription factor Sp1 and receptor of retinoic acid (RARE) in all tested samples of tumor tissue independently of the presence or absence of mRNA CD38. The obtained data suggest that in the tumor cells of patients with colorectal cancer the expression of the CD38 gene is heterogeneous.

[Immediate and long-term results of nephrectomy with inferior vena cava thrombectomy in renal cell carcinoma].

Results of treatment of 32 patients after nephrectomy with thrombectomy for renal cell carci-noma complicated by tumor thrombosis of the inferior vena cava were analyzed. The study in-cluded patients only with II - IV clot levels: 26 patients with T3b - the length of the thrombus 5.1 +/- 1.75 cm, 6 patients with T3c - the length of a thrombus - 14.8 +/- 0.98 cm. One patient (3.1%) died due to pulmonary artery thromboembolia in immediate postoperative period. 1-2 degrees Clavier Complications were observed in 11 patients, 3-4 degree - in two (6.2%) patients. 90.4% of patients had metastases in distant organs and (or) in the regional lymph nodes, which nega-tively affected the survival rates of patients - 5-year survival rate was 36%. The presence of lymphogenous metastases, MSKCC criteria were factors affecting survival rate. Survival rates of patients with T3b and T3C levels were not statistically different. The results of postoperative systemic targeted therapy were significantly statistically better than the results of immunotherapy.

[The serum levels of a soluble form of HLA I molecules in patients with lung cancer].

The paper presents the results of studying the content of soluble HLA I (sHLA-I) molecules in the blood samples from 56 patients first admitted to hospital for histologically verified lung cancer and 23 healthy donors matched by the patients' sex and age. The findings suggest that the development of Stages IB, IIA, and IIIA lung cancer is accompanied by a significant reduction in the serum levels of sHLA-I molecules. The serum concentration of sHLA-I molecules is decreased when the involvement foci are located in the lymph nodes of the lung root or in the mediastinum, but significantly increased when distant metastases emerge. The different morphological variants of the structure of a tumor do not differ in the serum content of sHLA molecules in the patients.

[Dynamics of the soluble CD50-antigen level in patients with breast cancer in the course of combined therapy]. / Dinamika urovnia rastvorimogo CD50-antigena u bol'nykh rakom molochnoi zhelezy v protsesse kompleksnogo lecheniia.

Immune enzyme assay with polyclonal and monoclonal antibodies was made use of to investigate the dynamic changes of soluble CD50-antigen in patients with breast cancer during chemotherapy and surgical treatment. A dependence of the content of the above antibody on a variety of parameters characterizing the tumor process and patients age was detected. The determination of a dynamic level of this protein provides for evaluating the efficiency of a treatment scheme.